The Cytotoxic Effects of Phenolic Compounds Extracted from Caps of White Beech Mushroom (Hypsizygus tessulatus) on HepG2 (Hepatocellular Cancer Cell Line(

Abstract

Cancer remains the world's leading cause of death, despite advancements in detection and treatment techniques. The current direction in scientific study is the development of novel anticancer medications derived from plants. Unlike other cancer therapies, phytochemicals are thought to work selectively and specifically, not to harm healthy cells. Liver cancer is a global health concern that has a high fatality rate. Because certain therapeutic mushroom extracts have anticancer qualities, they are becoming more and more popular. Using varying concentrations of white beech mushroom caps (15.60 μg/ml, 31.25 μg/ml, 62.5 μg/ml, 125 μg/ml, 250 μg/ml, and 500 μg/ml) for 48 hours at 37 °C, this study examined the function of extracts from the caps of the mushroom (Hypsizygus tessulatus) as a cytotoxic agent against two cell lines: the colon cell line cancer (HepG2) and the normal cell line HFF-1. The viability findings showed that the sensitivity of HepG2 was 532.88µg/ml. The study found that because white beech mushroom caps have little cytotoxicity on HFF-1, there is no danger involved in employing them in pharmaceuticals. The extract of white beech mushroom caps had a viability percentage of 55.84% on HepG2 cell lines at a 500 mg/ml concentration. Following 48 hours of incubation, there was no sensitivity and 100% viability in HFF-1 cells at control (IC50>100 µg/ml). In summary, the extract had an inhibitory impact on cancer cell lines, suggesting that it may be used as an anticancer medication.